Introduction
============

In plasma and in whole blood, total carnitine is present as free and acylcarnitine ester forms. Long-chain acylcarnitine esters are generated intracellularly for the transport of fatty acyl moieties through the mitochondrial inner membrane; in contrast, short- and medium-chain acylcarnitine esters are formed in peroxisomes intended for continuation of oxidation in mitochondria, whereas acylcarnitine esters of various chain lengths are generated in both organelles as a means of modulating the intracellular homeostasis of coenzyme A ([@B01],[@B02]).

The determination of free carnitine and acylcarnitine profiles by electrospray ionization tandem mass spectrometry (ESI-MS/MS) in plasma and dried blood spots (DBS) is aided by the fact that both underivatized and butyl esters of acylcarnitines yield a common product ion with a mass of 85 Da ([@B03]). Acylcarnitine profiling is a potent tool for the diagnosis and neonatal screening of fatty acid oxidation and organic acid metabolism disorders ([@B04]). Cut-off points for free carnitine and important acylcarnitine esters in DBS have been published in conjunction with evaluations of newborn screening programs ([@B05]-[@B07]). These cut-off points are tradeoffs between a high detection rate of affected neonates and an acceptable false-positive rate, and represent very high percentiles (e.g., 99.5th or 99.98th), which do not necessarily indicate reference intervals that can be applied for the diagnosis of symptomatic neonates. Few research investigations have reported more typical percentiles as reference limits (e.g., 5.0th-95.0th) for these metabolites in DBS ([@B08]).

Although acylcarnitine profiles for umbilical cord blood (CB) collected on filter paper have the potential to identify infants at risk of disorders with a relatively rapid progression after birth, few studies have established reference ranges for this clinical specimen ([@B08]-[@B11]). Moreover, significant differences are expected to exist between acylcarnitine profiles for CB and those for blood collected from newborn infants after birth due to the adaptation from a continuous supply of glucose *in utero* to a neonatal diet based on breast milk, and consequently to fat as a substantial source of energy ([@B12], [@B13]). These peculiarities could limit the value of CB acylcarnitine profiles in the detection of disorders of fatty acid oxidation and organic acid metabolism ([@B11]).

In the current study, we established reference intervals for free carnitine and acylcarnitine esters for CB and blood collected during the first few days of life (heel-prick blood, HPB) obtained from term neonates that were exclusively breastfed. The results obtained can be used to infer the effects of breastfeeding on the concentrations of these analytes in the first week of life.

Material and Methods
====================

Study population and blood sample collection
--------------------------------------------

CB was collected from 176 healthy neonates, 96 females and 80 males. The majority of the newborn infants (91%-155/171) were delivered by spontaneous vaginal delivery, while caesarean births and forceps-assisted vaginal births accounted for 8 (13/171) and 2% (3/171) of the deliveries, respectively. The mean (range) gestational age at birth was 39 weeks and 4 days (35 weeks and 5 days-42 weeks and 1 day); three post-term (≥42 weeks) and 6 preterm (\<37 weeks) infants, at first incorrectly evaluated as term infants, were excluded from the study. The neonates were categorized as small for gestational age (SGA), average for gestational age (AGA) or large for gestational age (LGA) if their birth weight was equal to or below the 2nd percentile, between the 2nd and the 98th percentiles or equal to or above the 98th percentile, respectively, according to the birth weight percentiles provided in the supplemental data of Oken et al. ([@B14]). A total of 163 term neonates were classified as AGA, 2 as SGA, and 2 as LGA. As the term SGA and LGA neonates were also excluded, our sample at the beginning of the study (CB collection) actually comprised 163 AGA term newborn infants. None of these had a diagnosis of birth asphyxia, defined as an Apgar score ≤6 at 5 min. CB samples were taken from vessels of the umbilical cord immediately after delivery and spotted on S&S Grade 903 filter paper (Whatman, UK), allowed to air dry for at least 4 h and stored in opaque envelopes at room temperature. As one CB sample was refused due to improper collection, it was possible to analyze 162 CB samples.

A second blood sample was prospectively collected by heel prick on day 4-8 from 106 neonates, and processed as CB samples. At this time, mothers were questioned about feeding practices, which were categorized according to the WHO definitions. Mothers reported exclusive breastfeeding for 99 newborn infants, while seven women stated partial breastfeeding, having introduced infant formula to their newborns.

Ethics approval and informed consent
------------------------------------

The study was approved by the Research Ethics Review Committee of "Instituto de Puericultura e Pediatria Martagão Gesteira, Universidade Federal do Rio de Janeiro - UFRJ", and was performed in accordance with Brazilian Guidelines and Regulating Norms on Research Involving Human Subjects and the Helsinki Declaration of 1975 as revised in 1996. Written informed consent was obtained from the mothers of all newborn infants.

Solvents, reagents and internal standards
-----------------------------------------

The reagents used included HPLC grade methanol and analytical grade acetic acid from Vetec (Brazil). HPLC grade acetonitrile was purchased from Tedia (USA) and 3 N HCl in n-butanol was purchased from Regis Technologies (USA). The deuterium-labeled free carnitine and L-acylcarnitines used as internal standards were purchased from Cambridge Isotope Laboratories (USA).

Sample preparation
------------------

Sample preparation was based on previously reported methods ([@B05]-[@B07], [@B15]). A single 3-mm diameter DBS (1/8 inch) was placed in a well of a 96-well microtiter polystyrene plate (Sarstedt, USA), followed by the addition of 90 µL of a methanol/water (3:1; v/v) extraction solution containing the deuterium-labeled internal standards. The concentrations of these standards were as follows: \[^2^H~9~\]-carnitine (^2^H~9~-C0), 0.76 µM; \[^2^H~3~\]-acetylcarnitine (^2^H~3~-C2), 0.19 µM; \[^2^H~3~\]-propionylcarnitine, (^2^H~3~-C3), 0.038 µM; \[^2^H~3~\]-butyrylcarnitine (^2^H~3~-C4), 0.038 µM; \[^2^H~9~\]-isovalerylcarnitine (^2^H~9~-C5), 0.038 µM; \[^2^H~3~\]-octanoylcarnitine (^2^H~3~-C8), 0.038 µM; \[^2^H~3~\]-myristoylcarnitine (^2^H~3~-C14), 0.038 µM; \[^2^H~3~\]-palmitoylcarnitine (^2^H~3~-C16), 0.076 µM. The microtiter plate was covered with sealing film and incubated for 30 min at 27°C with shaking at 750 rpm in an NCS incubator (Perkin Elmer, Finland). After seal removal, aliquots of the sample extracts (60 µL) were transferred to a polypropylene microtiter plate (USA Scientific, USA) and evaporated to dryness under synthetic air in a Micro-DS 96 sample concentrator (Porvair Sciences, UK). HCl in n-butanol (50 µL of a 3 N solution) was added to each sample well. Subsequently, the microtiter plate was resealed and incubated for 30 min at 60°C to achieve acylcarnitine derivatization. After the n-butanol derivatization, the solution was again evaporated to dryness in the sample concentrator. Finally, the samples were reconstituted with 75 µL acetonitrile-water (80:20, v/v) with 0.1% acetic acid, and the plate was covered with aluminum foil. The plate was then ready for ESI-MS/MS analysis after shaking at 750 rpm for 10 min at 27°C. Samples were generally prepared and analyzed within 2-3 days from collection.

Mass spectrometry
-----------------

An API 2000 triple-quadrupole tandem mass spectrometer (PE Sciex, Canada) operated in positive ion mode was used for acylcarnitine analysis. The system included also a Perkin Elmer series 200 autosampler and a Perkin Elmer series 200 liquid chromatography pump that were employed to transfer 10 µL of each sample directly into the ion spray probe at a solvent flow rate of 70 µL/min.

Acylcarnitines were analyzed by the precursor-ion scan of m/z 85 mode and scanning from m/z 200 to 550. Additionally, free carnitine (C0), acetylcarnitine (C2), and propionylcarnitine (C3) and their respective deuterium-labeled internal standards were analyzed in the multiple reaction monitoring (MRM) mode as recommended by Chace et al. ([@B15]) and by the directions for use of Perkin-Elmer\'s NeoGram amino acid and acylcarnitine tandem mass spectrometry kit (Perkin Elmer). The MRM transitions used in the analyses were from the n-butanol derivatized molecular ions of m/z 218, 227, 260, 263, 274, and 277 for C0, ^2^H~9~-C0, C2, ^2^H~3~-C2, C3, and ^2^H~3~-C3, respectively, to the product ion of m/z 103 for C0 and ^2^H~9~-C0 and m/z 85 for the other analytes.

The concentrations of free carnitine and acylcarnitines were calculated with the NeoGram software (Perkin Elmer) by comparing the measured analyte intensities to those of the internal standards. Data on linearity, functional sensitivity, reproducibility, recovery, interference, carryover, and drift for the mass spectrometry method used in this study were presented by the manufacturer to the Food and Drug Administration (FDA), and are available at the agency website \[<http://www.fda.gov/ohrms/dockets/dockets/04n0482/04n-0482-bkg00001-vol1.pdf>\].

Statistical analysis
--------------------

The Shapiro-Wilk test was used to assess whether the distributions of free carnitine and the acylcarnitine esters were normal. The Wilcoxon signed rank test was used to investigate significant differences in the distributions of the analytes in CB and HPB. Correlations between birth weight or gestational age and free carnitine or the various acylcarnitine ester concentrations in CB and HPB were tested by the Spearman correlation test. The level of significance was set at 0.05 in all statistical tests. Statistical analysis was performed using the Stata 9.1 software package (StataCorp, USA).

Results
=======

Distribution of analyte concentrations
--------------------------------------

The distributions of the concentrations of free carnitine and the various acylcarnitines in CB and in HPB were not normal, as indicated by the results of the Shapiro-Wilk W test for normality. The quantitatively major acylcarnitines in CB and HPB were the short-chain acylcarnitines C2 and C3, and the long-chain acylcarnitines palmitoylcarnitine (C16), stearoylcarnitine (C18), and oleoylcarnitine (C18:1). The acylcarnitine ester profile of CB differed slightly from that of HPB of 4- to 8-day-old infants in that the peak for C3 was relatively larger and those for the predominant long-chain acylcarnitines less significant. In addition, the order of concentration for the latter in CB, C16 \> C18 \> C18:1, differed from that found in HPB, C16 \> C18:1 \> C18 (see [Figure 1](#f01){ref-type="fig"}).

Figure 1.Acylcarnitine ester profiles obtained by a precursor of *m/z* 85 scan from dried blood spots (DBS) of a newborn infant. *A*, DBS of a whole cord blood (CB) sample. *B*, DBS of a heel-prick blood (HPB) sample collected on day 5 of life. Note that in HPB the peaks corresponding to long-chain acylcarnitines are more prominent than in CB. Stearoylcarnitine, C18 (*m/z* 484), appears as a larger peak than oleoylcarnitine, C18:1 (*m/z* 482), in CB. The reverse is true in HPB. The peak for propionylcarnitine, C3 (*m/z* 274), is usually larger in CB. Stable isotope-labeled acylcarnitine internal standards are identified by the number of deuterium atoms (d3 or d9). ^\*^Artifactual peak.

Box-plots for free carnitine and the predominant acylcarnitines are shown in [Figure 2](#f02){ref-type="fig"}.

Figure 2.Box-plots of the concentrations of free carnitine and the predominant acylcarnitines in dried blood spots of cord blood and heel-prick blood collected from 4- to 8-day-old newborns. *A*, Free carnitine (C0) and acetylcarnitine (C2). *B*, Propionylcarnitine (C3), palmitoylcarnitine (C16), stearoylcarnitine (C18), and oleoylcarnitine (C18:1). The boxes indicate the 1st and 3rd quartiles, and the central line is the median. The ends of the whiskers are 1.5 times the interquartile range below the 1st and above the 3rd quartile. Circles = outliers; x = extreme outliers; CB = umbilical cord blood; HPB = heel-prick blood sample collected during the first few days of life.

Descriptive statistics and reference intervals
----------------------------------------------

Descriptive statistics and reference intervals in CB and HPB for free carnitine, short-chain, and medium-chain acylcarnitines are summarized in [Table 1](#t01){ref-type="table"}. Similar parameters are summarized in [Table 2](#t02){ref-type="table"} for long-chain acylcarnitines and the acylcarnitine esters derived from dicarboxylic acids, and in [Table 3](#t03){ref-type="table"} for those derived from hydroxylated acids. Considering our sample size, we defined the limits of the reference intervals between the 2.5th and 97.5th percentiles, but the lower 2.5th percentile limit is devoid of clinical interest in most instances, with the exception of free carnitine and C2 for the diagnosis of primary systemic carnitine deficiency ([@B16]), and C16 and C18 for the diagnosis of carnitine palmitoyltransferase I (CPT I) deficiency ([@B17]).

Table 1.Concentrations of free carnitine and short-chain and medium-chain acylcarnitines in 162 cord blood samples and 106 paired heel-prick blood samples obtained 4-8 days after birth from healthy adequate for gestational age term newborn infants.AnalyteCord blood samplesHeel-prick blood samplesFree carnitineMedian27.05 (25.50-28.70)29.20 (26.41-31.06)[\*](#TFN02t01){ref-type="table-fn"}Range8.70-67.5014.30-62.302.5th-97.5th14.91-57.0814.84-56.84Short-chain acylcarnitines C2Median30.35 (28.10-31.10)32.95 (30.48-35.47)[\*](#TFN02t01){ref-type="table-fn"}Range13.60-65.9020.40-69.802.5th-97.5th17.51-49.6621.17-63.20 C3Median1.88 (1.69-2.01)1.68 (1.53-1.83)[\*](#TFN02t01){ref-type="table-fn"}Range0.60-6.570.75-5.732.5th-97.5th0.83-4.460.86-3.41 C4Median0.25 (0.23-0.28)0.30 (0.26-0.34)[\*](#TFN02t01){ref-type="table-fn"}Range0.05-1.300.09-1.202.5th-97.5th0.09-0.560.12-1.03 C5Median0.16 (0.14-0.18)0.24 (0.21-0.27)[\*](#TFN02t01){ref-type="table-fn"}Range0.03-0.420.07-0.882.5th-97.5th0.05-0.390.07-0.74 C5:1Median0.05 (0.05-0.06)0.06 (0.05-0.07)Range0.01-0.230.02-0.212.5th-97.5th0.02-0.160.02-0.18Medium-chain acylcarnitines C6Median0.08 (0.07-0.09)0.12 (0.10-0.13)[\*](#TFN02t01){ref-type="table-fn"}Range0.02-0.280.03-0.342.5th-97.5th0.02-0.190.04-0.32 C8Median0.09 (0.08-0.11)0.12 (0.10-0.14)Range0.02-0.420.03-0.402.5th-97.5th0.03-0.250.04-0.36 C10Median0.07 (0.06-0.07)0.10 (0.09-0.12)[\*](#TFN02t01){ref-type="table-fn"}Range0.02-0.200.03-0.322.5th-97.5th0.03-0.180.03-0.26 C10:1Median0.08 (0.07-0.09)0.12 (0.10-0.13)[\*](#TFN02t01){ref-type="table-fn"}Range0.02-0.270.03-0.362.5th-97.5th0.03-0.230.04-0.30 C10:2Median0.05 (0.04-0.05)0.05 (0.05-0.07)Range0.02-0.220.02-0.162.5th-97.5th0.03-0.130.03-0.16 C12Median0.08 (0.07-0.08)0.11 (0.09-0.13)[\*](#TFN02t01){ref-type="table-fn"}Range0.02-0.220.03-0.372.5th-97.5th0.02-0.190.04-0.32[^1][^2]

Table 2.Concentrations of long-chain acylcarnitines and acylcarnitine esters derived from dicarboxylic acids in 162 cord blood samples and 106 paired heel-prick blood samples obtained 4-8 days after birth from healthy adequate for gestational age term newborn infants.AnalyteCord blood samplesHeel-prick blood samplesLong-chain acylcarnitines C14Median0.14 (0.13-0.15)0.23 (0.19-0.25)[\*](#TFN02t01){ref-type="table-fn"}Range0.02-0.490.07-0.502.5th-97.5th0.05-0.340.08-0.43 C14:1Median0.06 (0.06-0.07)0.11 (0.09-0.12)[\*](#TFN02t01){ref-type="table-fn"}Range0.02-0.230.02-0.312.5th-97.5th0.02-0.160.02-0.31 C14:2Median0.04 (0.03-0.04)0.05 (0.04-0.06)Range0.01-0.170.02-0.132.5th-97.5th0.02-0.120.02-0.11 C16Median1.70 (1.60-1.82)2.16 (2.02-2.43)[\*](#TFN02t01){ref-type="table-fn"}Range0.58-4.240.81-4.892.5th-97.5th0.63-3.110.89-4.64 C16:1Median0.10 (0.10-0.12)0.15 (0.13-0.17)[\*](#TFN02t01){ref-type="table-fn"}Range0.03-0.300.02-0.522.5th-97.5th0.03-0.260.04-0.40 C16:2Median0.05 (0.05-0.06)0.06 (0.06-0.07)[\*](#TFN02t01){ref-type="table-fn"}Range0.01-0.190.01-0.232.5th-97.5th0.02-0.150.02-0.19 C18Median0.68 (0.65-0.72)0.77 (0.69-0.83)[\*](#TFN02t01){ref-type="table-fn"}Range0.32-2.070.29-2.132.5th-97.5th0.35-1.340.30-1.62 C18:1Median0.65 (0.60-0.68)1.34 (1.21-1.41)[\*](#TFN02t01){ref-type="table-fn"}Range0.26-1.480.47-3.022.5th-97.5th0.32-1.350.57-2.55 C18:2Median0.29 (0.26-0.31)0.31 (0.26-0.34)Range0.09-0.590.07-1.432.5th-97.5th0.13-0.500.11-0.90Acylcarnitine esters derived from dicarboxylic acids C3DCMedian0.10 (0.10-0.12)0.13 (0.10-0.15)[\*](#TFN02t01){ref-type="table-fn"}Range0.03-0.480.04-0.662.5th-97.5th0.04-0.350.04-0.43 C4DCMedian0.33 (0.30-0.37)0.39 (0.36-0.44)[\*](#TFN02t01){ref-type="table-fn"}Range0.11-0.990.09-1.052.5th-97.5th0.14-0.760.13-0.85 C5DCMedian0.04 (0.04-0.05)0.06 (0.05-0.07)[\*](#TFN02t01){ref-type="table-fn"}Range0.02-0.150.02-0.182.5th-97.5th0.02-0.120.02-0.14 C6DCMedian0.05 (0.04-0.05)0.06 (0.05-0.07)[\*](#TFN02t01){ref-type="table-fn"}Range0.01-0.230.02-0.322.5th-97.5th0.02-0.140.02-0.21[^3][^4]

Table 3.Concentrations of acylcarnitine esters derived from hydroxylated acids in 162 cord blood samples and 106 paired heel-prick blood samples obtained 4-8 days after birth from healthy adequate for gestational age term newborn infants.AnalyteCord blood samplesHeel-prick blood samplesC4OHMedian0.16 (0.14-0.18)0.26 (0.21-0.29)[\*](#TFN02t01){ref-type="table-fn"}Range0.04-0.650.04-0.832.5th-97.5th0.05-0.400.08-0.67C5OHMedian0.18 (0.16-0.19)0.19 (0.17-0.20)Range0.03-0.700.08-0.502.5th-97.5th0.07-0.390.09-0.44C12OHMedian0.03 (0.03-0.04)0.05 (0.04-0.06)[\*](#TFN02t01){ref-type="table-fn"}Range0.01-0.110.01-0.182.5th-97.5th0.02-0.090.02-0.15C14OHMedian0.04 (0.03-0.04)0.04 (0.04-0.05)[\*](#TFN02t01){ref-type="table-fn"}Range0.01-0.130.02-0.132.5th-97.5th0.02-0.090.02-0.11C16OHMedian0.04 (0.03-0.04)0.05 (0.04-0.06)[\*](#TFN02t01){ref-type="table-fn"}Range0.01-0.120.01-0.152.5th-97.5th0.02-0.090.02-0.13C16:1OHMedian0.07 (0.06-0.07)0.07 (0.06-0.08)Range0.02-0.180.02-0.202.5th-97.5th0.02-0.160.02-0.19C18OHMedian0.03 (0.02-0.03)0.04 (0.03-0.04)[\*](#TFN02t01){ref-type="table-fn"}Range0.01-0.100.01-0.122.5th-97.5th0.01-0.080.02-0.10C18:1OHMedian0.03 (0.03-0.03)0.04 (0.04-0.05)[\*](#TFN02t01){ref-type="table-fn"}Range0.01-0.150.01-0.192.5th-97.5th0.01-0.100.02-0.11C18:2OHMedian0.10 (0.09-0.11)0.13 (0.11-0.14)[\*](#TFN02t01){ref-type="table-fn"}Range0.03-0.320.04-0.362.5th-97.5th0.04-0.230.04-0.26[^5][^6]

The levels of the quantitatively major long-chain acylcarnitines (C16, C18, C18:1) increased significantly in the first week of life - increase of the median: 27% (P \< 0.0001), 12% (P = 0.0196), and 109% (P \< 0.0001), respectively ([Table 2](#t02){ref-type="table"}). Free carnitine and C2 medians had a modest increase, which was nevertheless statistically significant: 8% (P = 0.0327) and 11% (P \< 0.0001), respectively ([Table 1](#t01){ref-type="table"}). C3 presented a different behavior, decreasing 9% (P = 0.0022) in the period ([Table 1](#t01){ref-type="table"}).

The differences between the medians of the concentrations in CB and HPB of the majority of quantitatively minor short-chain acylcarnitines ([Table 1](#t01){ref-type="table"}), medium-chain acylcarnitines ([Table 1](#t01){ref-type="table"}), quantitatively minor long-chain acylcarnitines ([Table 2](#t02){ref-type="table"}), and of acylcarnitine esters derived from dicarboxylic ([Table 2](#t02){ref-type="table"}) and hydroxylated acids ([Table 3](#t03){ref-type="table"}) were significant when evaluated by Wilcoxon\'s signed rank test. Similar to the quantitatively major acylcarnitine esters (C2, C3, C16, C18, C18:1), they tended to increase during the first week of life. The exceptions were 3-hydroxyisovalerylcarni-tine (C5OH), tiglylcarnitine (C5:1), octanoylcarnitine (C8), decadienoylcarnitine (C10:2), tetradecadienoylcarnitine (C14:2), 3-hydroxyhexadecenoylcarnitine (C16:1OH), and linoleylcarnitine (C18:2), whose median concentrations in CB and HPB did not show significant differences.

Correlations between birth weight or gestational age and the analyte concentrations
-----------------------------------------------------------------------------------

For our sample of AGA term newborn infants, the correlations between birth weight or gestational age and the concentrations of free carnitine or the various acylcarnitine esters were very weak (*r* ≤ 0.20) for all analytes in CB, and in most instances the correlations were also nonsignificant, P \> 0.05 (see supplemental data, [Table 1](#t01){ref-type="table"}). The exceptions were the significant (P ≤ 0.05) albeit very weak correlations found in CB between birth weight and 3-hydroxybutyrylcarnitine, C4OH (*r* = -0.1689; P = 0.0327), 3-hydroxytetradecanoylcarnitine, C14OH (*r* = 0.1684; P = 0.0333), and 3-hydroxyoctadecenoylcarnitine, C18:1OH (*r* = -0.1625; P = 0.0333), and between gestational age and C4OH (*r* = -0.1602; P = 0.0479), isovalerylcarnitine, C5 (*r* = 0.1638; P = 0.0430), and hexanoylcarnitine, C6 (*r* = -0.1912; P = 0.0179).

In HPB, although the correlations between birth weight or gestational age and the majority of the analytes were also very weak and non-significant (see supplemental data, [Table 2](#t02){ref-type="table"}), few acylcarnitine ester concentrations in HPB showed weak (0.20 \< *r* ≤ 0.40) and significant correlations with birth weight as follows: C3 (*r* = 0.2099; P = 0.0316), C4OH (*r* = 0.2464; P = 0.0113), 3-hydroxydodecanoylcarnitine, C12OH (*r* = 0.2511; P = 0.0098), and hexadecenoylcarnitine, C16:1 (*r* = 0.2072; P = 0.0340). In turn, C14OH (*r* = 0.2202; P = 0.0277) and tetradecadienoylcarnitine, C14:2 (*r* = 0.2852; P = 0.0040), in HPB showed a weak and significant correlation with gestational age.

Discussion
==========

Few studies have described reference limits for free carnitine and acylcarnitine esters in CB by ESI-MS/MS ([@B08],[@B09],[@B11],[@B18]-[@B22]). In these studies, however, different specimens were used in the analyses. As done in the present study, three of them used DBS of whole CB in order to obtain a full carnitine and acylcarnitine profile ([@B08],[@B09],[@B11]). On the other hand, Talián et al. ([@B18]) employed dried cord plasma spotted on filter paper cards. Osorio and Pourfarzam ([@B20]) favored this specimen for the analysis of total and free carnitine but turned to DBS of whole CB in order to obtain the full acylcarnitine profile ([@B19]). Chace et al. ([@B21]) compared the results for total and free carnitine in whole cord blood and plasma, both spotted on filter paper. [Table 4](#t04){ref-type="table"} compares the concentrations of free carnitine and major acylcarnitines reported by these various investigators to those obtained in the present study.

Table 4.Concentrations of free carnitine and major acylcarnitines in cord blood samples reported in the literature compared with those obtained in the present study.ReferenceNSampleAnalyte (mean ± SD, 1.96 SD or SEM in µM, see legend)C0C2C3C16C18C18:1Present study162A28.47 ± 9.7930.75 ± 8.491.98 ± 0.871.73 ± 0.600.73 ± 0.260.69 ± 0.25Meyburg et al. ([@B09])70A31.60 ± 10.2010.30 ± 3.102.00 ± 0.602.60 ± 0.801.30 ± 0.401.10 ± 0.40Osorio and Pourfarzam ([@B19])130A-13.79 ± 4.611.51 ± 0.642.63 ± 1.300.89 ± 0.410.82 ± 0.38Cavedon et al. ([@B08])67A29.10 ± 2.3531.80 ± 1.753.50 ± 0.252.90 ± 0.20-1.15 ± 0.13Honzík et al. ([@B22])33A46.87 ± 13.90\-\-\-\--Chace et al. ([@B21])50A21.59 ± 10.52\-\-\-\--B12.95 ± 4.85\-\-\-\--Osorio and Pourfarzam ([@B20])130B18.50 ± 3.40\-\-\-\--Talián et al. ([@B18])20B20.00 ± 1.3011.24 ± 1.560.22 ± 0.020.15 ± 0.010.07 ± 0.010.12 ± 0.01

ReferenceNSampleAnalyte (95% reference limits in µM)C0C2C3C16C18C18.1Present study162A14.91-57.0817.51-49.660.83-4.460.63-3.110.35-1.340.32-1.35Walter et al. ([@B11])12,952A14.41-57.91-0.79-3.440.87-4.810.23-1.800.29-1.84[^7]

There is no consensus concerning the clinical specimen (plasma, erythrocytes, or whole blood) that would best reflect the carnitine status of various body compartments of newborn infants, justifying its exclusive recommendation for the detection of eventual carnitine metabolism disorders in this population ([@B23]).

Various methods have been reported for the analysis of free carnitine and acylcarnitines in clinical specimens, including fast atom bombardment tandem mass spectrometry (FAB-MS/MS) ([@B24]), radioisotopic exchange-highperformance liquid chromatography (RIE-HPLC) ([@B25]), and gas chromatography-mass spectrometry (GC-MS) ([@B26]). In the case of acylcarnitine profiling by RIE-HPLC, the method exploits the selectivity of carnitine acetyltransferase (CAT) to label acylcarnitines with a radioactive marker. However, long-chain acylcarnitines and dicarboxylic acylcarnitines are not good substrates for CAT, limiting the application of this method ([@B25]). Acylcarnitines are charged, polar, and nonvolatile compounds, therefore they are not good candidates for GC-MS techniques, requiring complex derivatization reactions under forced conditions ([@B27]).

FAB-MS/MS was introduced by Millington et al. ([@B24]) for acylcarnitine detection. This method allowed the metabolic profiling of acylcarnitines from plasma and DBS, as a result of the significant improvement in sensitivity that was achieved ([@B27]). Moreover, with the use of continuous flow FAB (CF-FAB), analysis time was significantly reduced. ESI-MS/MS, the method employed in the present study, was initially proposed by Rashed et al. ([@B27],[@B28]) as a more robust and sensitive alternative technique to FAB-MS/MS for acylcarnitine profiling in DBS. ESI-MS/MS does not require frequent instrument cleaning and permits higher flow rates than CF-FAB, rendering the method suitable for automation and high sample throughput.

Derivatized ESI-MS/MS assays are employed by the majority of newborn screening laboratories around the world, but it is possible to detect acylcarnitines as their native free acids by underivatized methods. These latter methods have the disadvantage of not differentiating some isobaric acylcarnitines and of eliciting a less intense response from dicarboxylic acid acylcarnitines ([@B29]).

It is useful to compare our finding of a significant although modest 8% increase in free carnitine concentration in the first week of life to the results of other investigators. Meyburg et al. ([@B09]) and Cavedon et al. ([@B08]) found that free carnitine concentrations remained unchanged in the first days of life by comparing CB samples to paired samples from 5-day-old infants or to unpaired samples from 3-to-6-day-old infants, respectively. In turn, Chace et al. ([@B21]) found that free carnitine levels in CB samples from a small cohort of 50 full-term newborns were 48% lower than the levels in HPB from a large cohort (N = 24,644) of 2 ± 1-day-old infants. The huge difference in sample size between the two cohorts precludes any further interpretation. Wilcken et al. ([@B16]) found a small (3.4%) increase in median free carnitine levels in the neonatal population from 26.6 µM at day 2 (N = 13,311) to 27.5 µM at day 5-8 (N = 5.546). Therefore, our results agree with the finding from this large-scale study of a small increase in free carnitine levels during the early neonatal period. [Table 5](#t06){ref-type="table"} summarizes the findings of the studies that compared the concentrations of free carnitine for at least two time points during the early neonatal period.

Table 5.Variations in the concentrations of free carnitine detected in studies that compared at least two time points during the early neonatal period.ReferenceNCord blood2nd sample (age in days)NHeel-prick bloodPresent study16227.05 (15.73-47.27)[‡](#TFN03t06){ref-type="table-fn"}4-810629.20 (15.91-53.72)[‡](#TFN03t06){ref-type="table-fn"}[†](#TFN06t06){ref-type="table-fn"}Meyburg et al. ([@B09])7031.60 ± 10.20[§](#TFN04t06){ref-type="table-fn"}57030.60 ± 10.60[§](#TFN04t06){ref-type="table-fn"}Wilcken et al. ([@B16])13,31126.60 (14.00-52.00)^a^[‡](#TFN03t06){ref-type="table-fn"}5-85,54627.50 (14.30-49.60)[‡](#TFN03t06){ref-type="table-fn"}[††](#TFN07t06){ref-type="table-fn"}Chace et al. ([@B21])5021.59 ± 10.52[§](#TFN04t06){ref-type="table-fn"}2 ± 1[§](#TFN04t06){ref-type="table-fn"}24,64446.85 ± 21.19[§](#TFN04t06){ref-type="table-fn"}[††](#TFN07t06){ref-type="table-fn"}Cavedon et al. ([@B08])6729.10 (26.80-31.50)[¶](#TFN05t06){ref-type="table-fn"}3-611729.40 (27.60-31.20)[¶](#TFN05t06){ref-type="table-fn"}[^8][^9][^10][^11][^12][^13][^14]

Possibly the fraction of exclusively breastfed newborn infants has a great impact on free carnitine levels during this period, since there is an increased carnitine concentration in human milk during the first two weeks after delivery ([@B30]) and the bioavailability of human milk carnitine is superior to that of cow milk or cow milk protein-based infant formula ([@B12],[@B31]).

In contrast, similar to the studies of Meyburg et al. ([@B09]) and Cavedon et al. ([@B08]), we found lower concentrations of almost all acylcarnitines in CB when compared to HPB obtained from the same newborn infants when they were 4 to 8 days old (paired samples, see [Figures 1](#f01){ref-type="fig"} and [2](#f02){ref-type="fig"}). This finding could be attributed to the low plasma lipid levels at birth due to a limited fatty acid transfer across the human placenta ([@B32]). Moreover, the increase in the levels of several acylcarnitines in the early neonatal period is a consequence of the process of adaptation to breast milk as the sole source of nutrients and energy, with its large concentration of fatty acids, primarily derived from triglycerides, which account for 35-50% of the total daily energy supply of the newborn infant ([@B33]). Further support of this assumption is the fact that the predominant long-chain acylcarnitines in the early neonatal period, C16 and especially C18:1 (see [Figures 1](#f01){ref-type="fig"} and [2](#f02){ref-type="fig"}), are the acylcarnitine esters of the quantitatively major fatty acids in breast milk, palmitic (16:0) and oleic (18:1ω9) acids, which comprise 35-70% of breast milk total fatty acids ([@B34]). Conversely, the quantitatively major acylcarnitines in CB, C16 and C18 (see [Figures 1](#f01){ref-type="fig"} and [2](#f02){ref-type="fig"}), correspond to the predominance of palmitic (16:0) and stearic (18:0) acids in the fraction of nonesterified fatty acids in maternal blood and CB ([@B32]).

Propionylcarnitine (C3) behaved differently as its median concentration in CB was significantly higher than that in HPB (see [Figure 2](#f02){ref-type="fig"}). Cavedon et al. ([@B08]) obtained similar results, although comparing unpaired samples. Meyburg et al. ([@B09]), in contrast, showed an increase in mean C3 concentration in paired HPB samples from 5-day-old newborn infants when compared to CB samples. Walter et al. ([@B11]), in a large-scale cohort study, found many newborn infants with very high C3 levels in CB that decreased to normal levels when a second newborn screening sample was collected. We also observed the presence of extreme outliers of C3 concentration in CB samples (see [Figure 2](#f02){ref-type="fig"}).

There are some case series reports indicating the clinical utility of free carnitine and acylcarnitine ester profile in CB for the selective screening of high-risk newborn infants immediately after birth. Patterson et al. ([@B35]) reported a case of isovaleric acidemia and two cases of medium-chain acyl-coenzyme A dehydrogenase deficiency (MCADD) in newborn infants with a positive family history that were diagnosed by abnormalities in relevant acylcarnitine species in CB. They also ruled out the diagnosis of MCADD in four other high-risk newborn infants whose C8 levels in CB were found to be normal. Nassogne et al. ([@B36]) reported the diagnosis of CPT II deficiency in a newborn sibling of an affected proband by an acylcarnitine ester profile of CB. An increase of long-chain acylcarnitines from C12 to C18 was demonstrated in CB while the organic acid profile of the first urine samples did not show any alteration. Isackson et al. ([@B37]) described a newborn infant along with other four patients, whose prior sibling had died at birth, who presented significant elevations in long-chain CB acylcarnitines and a clinical course consistent with the severe, lethal neonatal form of CPT II deficiency, confirmed by CPT II assay in cultured skin fibroblasts and genomic DNA analysis. Yokoi et al. ([@B38]) reported a Japanese neonate with holocarboxylase synthetase deficiency and a positive family history who had received prenatal administration of biotin from 33 weeks\' gestation and whose serum cord blood sample showed elevated C3 and C5OH levels.

Since CB can reflect changes in maternal blood rather than the baby\'s situation, acylcarnitine analysis in CB has revealed maternal metabolic disease in completely asymptomatic or vaguely symptomatic mothers ([@B10], [@B11]). Vijay et al. ([@B10]) reported the identification of four unrelated women from consanguineous families of Asian origin discovered to have primary systemic carnitine deficiency as a consequence of finding low free carnitine concentrations in CB or HPB samples from their infants. Santos et al. ([@B39]) diagnosed MCADD in a woman who presented acute fatty liver at the 39th week of pregnancy and whose unaffected infant was identified with high C8 levels in CB. Interestingly, in both reports the abnormal results were initially attributed to metabolic disorders affecting the newborn infants, but the detection of normal profiles in follow-up samples made the authors turn their attention to the babies\' mothers.

These reports demonstrate that the collection of CB at the time of delivery for the analysis of free carnitine and acylcarnitines can be appropriate for the selective screening of high-risk newborn infants, including those with a family history of affected siblings, perinatal or neonatal death, or who are offspring of consanguineous marriages or of mothers affected by acute fatty liver. This is especially true in the Brazilian scenario where newborn screening, although currently established to be undertaken at 3-7 days, shows a poor timeliness in many Brazilian states ([@B40]), which is unacceptable for the purpose of selective screening of high-risk newborn infants.
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[^1]: Concentrations are reported in µM. Data are reported as median (95%CI), range and 2.5th and 97.5th percentiles.

[^2]: P \< 0.05 compared to cord blood samples (Wilcoxon\'s signed rank test).

[^3]: Concentrations are reported in µM. Data are reported as median (95%CI), range and 2.5th and 97.5th percentiles.

[^4]: P \< 0.05 compared to cord blood samples (Wilcoxon\'s signed rank test).

[^5]: Concentrations are reported in µM. Data are reported as median (95%CI), range and 2.5th and 97.5th percentiles.

[^6]: P \< 0.05 compared to cord blood samples (Wilcoxon\'s signed rank test).

[^7]: The data for most studies, including the present one, are reported as means ± SD, while for Cavedon et al. ([@B08]) they are means ± 1.96 SD (95% confidence interval), and for Talián et al. ([@B18]), means ± SEM. N = total number of samples. *A* = whole cord blood spotted on filter paper; *B* = cord blood plasma spotted on filter paper.

[^8]: Concentrations are reported as µM for cord blood and heel-prick blood samples.

[^9]: The results for Wilcken et al. ([@B16]) refer to heel-prick blood samples collected on the second day of life. Age = age of the neonates in days at the time of the second matched sample collection for the present study and that of Meyburg et al. ([@B09]). For the other studies, the second samples were unmatched and obtained from another group of neonates at the age shown in the table.

[^10]: Median (2.5th and 97.5th percentiles).

[^11]: Means ± SD.

[^12]: Means ± 1.96 SD (95% confidence interval).

[^13]: P \< 0.05 for differences between the medians (present study). The differences between the means of the concentrations of the two samples were not significant in Cavedon et al. ([@B08]) and Meyburg et al. ([@B09]).

[^14]: Significance test for the differences observed was not performed.
